Island Pharmaceuticals Limited (ILA.AX)
AUD 0.17
(-2.86%)
AUD 0.17
(-2.86%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 2.56 Million AUD | 25.14% |
| 2023 | 2.04 Million AUD | -58.17% |
| 2022 | 4.89 Million AUD | -26.18% |
| 2021 | 6.63 Million AUD | 39034664.71% |
| 2020 | 17.00 AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 2.56 Million AUD | 45.2% |
| 2024 Q2 | 1.76 Million AUD | 0.0% |
| 2024 Q1 | 1.76 Million AUD | -63.95% |
| 2024 Q4 | 2.56 Million AUD | 0.0% |
| 2024 FY | 2.56 Million AUD | 25.14% |
| 2023 Q2 | 3.58 Million AUD | 0.0% |
| 2023 Q1 | 3.58 Million AUD | -26.83% |
| 2023 Q3 | 2.04 Million AUD | -42.83% |
| 2023 Q4 | 4.89 Million AUD | 139.06% |
| 2023 FY | 2.04 Million AUD | -58.17% |
| 2022 Q2 | 5.9 Million AUD | 0.0% |
| 2022 Q1 | 5.9 Million AUD | -10.94% |
| 2022 FY | 4.89 Million AUD | -26.18% |
| 2022 Q4 | 4.89 Million AUD | 0.0% |
| 2022 Q3 | 4.89 Million AUD | -17.11% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | 6.63 Million AUD | 39034664.71% |
| 2021 Q4 | 6.63 Million AUD | 0.0% |
| 2021 Q3 | 6.63 Million AUD | 0.0% |
| 2020 FY | 17.00 AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AdAlta Limited | 5.57 Million AUD | 53.984% |
| Acrux Limited | 8.96 Million AUD | 71.388% |
| Actinogen Medical Limited | 21.31 Million AUD | 87.967% |
| AnteoTech Limited | 9.38 Million AUD | 72.664% |
| Argenica Therapeutics Limited | 16.37 Million AUD | 84.342% |
| Arovella Therapeutics Limited | 13.28 Million AUD | 80.696% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -53.43% |
| Alterity Therapeutics Limited | 19.22 Million AUD | 86.66% |
| Amplia Therapeutics Limited | 14.84 Million AUD | 82.725% |
| Avecho Biotechnology Limited | 7.31 Million AUD | 64.963% |
| Bio-Gene Technology Limited | 3.15 Million AUD | 18.835% |
| Biome Australia Limited | 8.27 Million AUD | 69.016% |
| Biotron Limited | 493.47 Thousand AUD | -419.675% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 97.72% |
| BTC Health Limited | 5.14 Million AUD | 50.193% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | 83.209% |
| CSL Limited | 56.93 Billion AUD | 99.995% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 98.342% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 98.89% |
| Cynata Therapeutics Limited | 8.38 Million AUD | 69.428% |
| Dimerix Limited | 32.07 Million AUD | 92.006% |
| EZZ Life Science Holdings Limited | 25.55 Million AUD | 89.964% |
| Hexima Limited | 2.26 Million AUD | -13.022% |
| Immuron Limited | 15.54 Million AUD | 83.508% |
| Immutep Limited | 147.44 Million AUD | 98.261% |
| Imugene Limited | 151.39 Million AUD | 98.306% |
| Invex Therapeutics Ltd | 6.12 Million AUD | 58.097% |
| Memphasys Limited | 12.43 Million AUD | 79.369% |
| Nanollose Limited | 241.95 Thousand AUD | -959.913% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 98.966% |
| Noxopharm Limited | 6.78 Million AUD | 62.197% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | 52.823% |
| Nyrada Inc. | 5.9 Million AUD | 56.588% |
| Orthocell Limited | 26.61 Million AUD | 90.365% |
| PharmAust Limited | 11.12 Million AUD | 76.948% |
| Patrys Limited | 4.16 Million AUD | 38.377% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 90.637% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | 76.419% |
| Prescient Therapeutics Limited | 20.39 Million AUD | 87.425% |
| PYC Therapeutics Limited | 91.23 Million AUD | 97.189% |
| Race Oncology Limited | 20.22 Million AUD | 87.323% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | 96.44% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | 59.739% |
| Starpharma Holdings Limited | 36.81 Million AUD | 93.034% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 99.356% |
| Tissue Repair Ltd | 19.38 Million AUD | 86.774% |
| Zelira Therapeutics Limited | 5.18 Million AUD | 50.525% |